What happened
Beyond Air, Inc. (NASDAQ: XAIR) said preliminary, unaudited revenue for the quarter ended September 30, 2026 was about $2.3 million. That was the company’s highest quarterly revenue so far. Revenue rose about 30% from the quarter ended June 30, 2026 and 27% from the same quarter last year. Management said the quarter reflected continued adoption of first-generation LungFit PH.
Beyond Air said its second-generation system remains under FDA review. It said revenue growth reflects continued adoption of LungFit PH and the value hospitals see in its cylinder-free nitric oxide technology. The company also said adding transport capability would qualify it as a single source nitric oxide provider, which it said is the current standard across most U.S. hospital systems.
The company said the 2026 figure excludes revenue from the second-generation LungFit PH system. It said the 2027 range includes anticipated revenue from the second-generation system, pending FDA approval.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Preliminary revenue for the quarter ended September 30, 2026 | $2.3 million | +27% | Beyond Air press release, Exhibit 99.1 |
| Sequential revenue growth | approximately 30% | Beyond Air press release, Exhibit 99.1 | |
| CY2026 revenue guidance | $8 million | Beyond Air press release, Exhibit 99.1 | |
| CY2027 revenue guidance | $16 million to $18 million | Beyond Air press release, Exhibit 99.1 |
Read more: Beyond Air (XAIR) stock analysis and investment case
Why it matters
OptimistFi's case is that Beyond Air needs hospital adoption of LungFit PH to grow revenue before dilution pressure becomes a problem. This filing supports that case by showing continued adoption and keeping both revenue targets in place. The preliminary $2.3 million was about 28.75% of the $8 million CY2026 guidance floor, OptimistFi's calculation from the filing's figures. That gives investors a yardstick for judging whether the current adoption rate can support the full-year target.
The figure is preliminary and unaudited. It is still subject to closing procedures and review, and actual results may differ materially. The 2027 range already assumes anticipated revenue from the second-generation system, but only pending FDA approval. That leaves near-term adoption as the key test until the later product clears review.
Browse: stock research on every company OptimistFi covers
What's next
Beyond Air said it will report complete financial results for the quarter ended September 30, 2026 in November 2026. That report will show whether the preliminary figure holds after closing and review. A result near the preannouncement would support the adoption trend, while a lower figure would weaken it.
More from OptimistFi
- XAIR stock: the Beyond Air thesis, its status and the next test to watch
- Can Atmus Filtration Technologies Inc. (NYSE: ATMU) Use Cash Flow to Cut Debt?
- United States Brent Oil Fund, LP (NYSE Arca: BNO) Tracks a Supply Gap
- Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC Exhibit 99.1 press release — Beyond Air preannounces preliminary revenue and reaffirms revenue guidance, dated October 8, 2026.
- SEC Form 8-K — Current report furnished on October 8, 2026, incorporating the press release as Exhibit 99.1.
Read the full OptimistFi thesis on Beyond Air, Inc.: https://optimistfi.com/stocks/XAIR
See what would break the Beyond Air, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Beyond Air, Inc. investment case, its status and the next test to watch live on the Beyond Air, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
